Company release 27 Dec 2017 at 9:00 am
Company release 27 Dec 2017 at 9:00 am
Herantis Pharma expands on timeline for Lymfactin® studies
Herantis Pharma Plc
Company release 27 December 2017 at 9:00 am
Herantis Pharma Plc’s (“Herantis”) announces a slight delay in completing patient recruitment in its clinical Phase 1 study with the company’s investigational gene therapy product Lymfactin®. Patient recruitment is expected to be completed in the first quarter of 2018 instead of by the end of 2017 as previously estimated and announced.
Thanks to the data cumulated so far meeting expectations in the Phase 1 study, Herantis is preparing the submission of a clinical trial application for a Phase 2, randomized, placebo-controlled clinical trial on Lymfactin® in the first quarter of 2018.
“The delay in in the Phase 1 study patient recruitment is due to a higher amount of screening failures than expected”, comments Pekka Simula, Herantis’ CEO. “Safety of the patients is always our first priority and we are happy to accept a small delay as the price of compliance with a strict protocol to minimize any risks.”
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225
About breast-cancer associated lymphedema
Approximately 20% of breast cancer patients who undergo axillary lymph node dissection develop secondary lymphedema, a chronic, progressive, disabling and disfiguring disease that severely affects quality of life. Symptoms include a chronic swelling of an upper limb, thickening and hardening of skin, loss of mobility and flexibility, pain, and susceptibility to secondary infections. Secondary lymphedema is currently treated with compression garments, special massage, and exercises. While these therapies may relief the symptoms in some patients they do not cure lymphedema, which is caused by damage to the lymphatic system. There are currently no approved medicines for the treatment of this condition.
Lymfactin® is an investigational gene therapy expressing the growth factor VEGF-C specific to the development of lymphatic vessels. Based on preclinical studies Lymfactin® triggers the growth of new functional lymphatic vasculature in the damaged area and thus repairs the underlying cause of secondary lymphedema. Lymfactin®, patented by Herantis, is based on the internationally renowned scientific research of academy professor Kari Alitalo and his research group, a national centre of excellence at the University of Helsinki. Herantis also holds patents for a combination therapy, which may expand the use of Lymfactin® in other lymphedemas. See our introductory video on Lymfactin®: https://herantis.com/media/videos/
About drug development in general
Drug development projects can usually be divided in two stages: The preclinical stage, and the clinical stage involving human subjects. The clinical stage can be further broken in three formal phases. Phase 1 clinical studies assess the safety of a drug candidate in human subjects. In Phase 2, the optimal dosing and possible efficacy in the treatment of a particular disease is studied. Phase 3 studies finally aim to establish a statistical proof of safety and efficacy of the drug candidate in typically hundreds or thousands of patients for market approval. Drug development can take 10-15 years from the first preclinical studies to market approval.
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine for breakthrough in unmet clinical needs. Our first-in-class assets are based on globally leading scientific research in their fields: CDNF for disease modification in neurodegenerative diseases, primarily Parkinson’s and ALS; and Lymfactin® for breast cancer associated lymphedema, with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.